Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)
Partnership Expansion:
Pfizer and PostEra have expanded their AI-driven drug discovery partnership to include Antibody-Drug Conjugates (ADCs), increasing the total partnership value to $610 million134.
AI Lab Expansion:
The AI Lab, initially valued at $260 million, will now include additional programs for small molecule drug discovery and ADC development, leveraging PostEra’s Proton platform14.
ADC Initiative:
The ADC partnership focuses on optimizing payload properties to improve efficacy and safety profiles, with Proton playing a key role in tackling these challenges13.
Financial Terms:
PostEra will receive an upfront payment of $12 million and is eligible for additional milestone payments and tiered royalties on any approved products14.
Prior Successes:
The collaboration has already demonstrated the real-world impact of AI-driven drug discovery in achieving preclinical milestones faster than expected, as shown in peer-reviewed publications with Pfizer13.
Proton Platform:
PostEra’s proprietary machine-learning platform, Proton, integrates medicinal chemistry design hypotheses with synthesis-aware technologies to design, create, and test novel molecules13.
ADC Market:
The global ADC market is currently valued at over $4.0 billion and is projected to reach $14.0 billion by 2027, highlighting the potential for AI-driven ADC development25.
Sources:
1. https://www.biopharmatrend.com/post/1098-postera-and-pfizer-expand-610m-partnership-for-ai-driven-adc-development/
2. https://ir.lanternpharma.com/news-events/press-releases/detail/128/lantern-pharma-leverages-ai-platform-radr-to-develop
3. https://xrphmagazine.ai/pfizer-expands-ai-partnership-with-postera-to-include-adcs/
4. https://www.pharmtech.com/view/postera-expands-pfizer-partnership-ai-lab-adc-collaborations
5. https://www.adcreview.com/news/using-ai-in-the-developing-novel-adcs-lantern-pharma-and-bielefeld-university-to-cooperate/